melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that, while c-Kit protein was readily observed in normal human neonatal and adult melanocytes, the majority of cell lines established from human melanoma samples did not express detectable levels of c-kit mRNA or protein.
|
1371338 |
1992 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine whether human tumor cell lines display c-kit receptors, we performed binding experiments with 125I-SCF on a breast carcinoma cell line (Du4475), a gastric carcinoma cell line (KATO III), a melanoma cell line (HTT144), as well as two small cell lung carcinoma cell lines (H69 and H128).
|
1378316 |
1992 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
|
7530509 |
1995 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.
|
7530509 |
1995 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We therefore examined KIT expression and function in human melanomas.
|
7687762 |
1993 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into the c-KIT negative highly metastatic human melanoma cell line A375SM and subsequently analysed its tumorigenic and metastatic potential.
|
8957075 |
1996 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells.
|
9171936 |
1997 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
|
9438854 |
1998 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
|
9438854 |
1998 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.
|
9632718 |
1998 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.
|
9687504 |
1998 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, exposure of c-KIT-positive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for c-KIT, triggered apoptosis of these cells but not of normal melanocytes.
|
9810513 |
1998 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
|
11276010 |
2001 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
|
11276010 |
2001 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2.
|
12789289 |
2003 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry revealed progressive loss of the AP-2alpha and c-kit proteins in primary melanomas and metastases when compared with naevi.
|
14517845 |
2003 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
|
14634801 |
2004 |
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
|
15145934 |
2004 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
|
15790786 |
2005 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
|
15790786 |
2005 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of a c-kit-activating mutation in metastatic malignant melanoma suggests that a small number of melanomas may progress by a somatic mutation of the c-kit gene.
|
15948115 |
2005 |
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
|
16046538 |
2005 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine whether CD117 immunoreactivity may be useful in separating melanoma from clear cell sarcoma.
|
16519562 |
2006 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
|
16647948 |
2006 |